The abstract is read at the publisher; the summary is JClub's.
Gut microbiota-derived metabolites are key regulators of immunometabolism in inflammatory bowel disease (IBD), linked to altered mitochondrial function and host metabolic pathways in intestinal epithelial and immune cells.
- Why it matters: IBD involves profound metabolic changes in both epithelial and immune compartments, but how microbial metabolites coordinate immunometabolic crosstalk—and how to target it therapeutically—remains underexplored.
- What they did: This review synthesizes emerging concepts on how microbial metabolites mediate host–microbe communication, reshaping mitochondrial functions and immune metabolic pathways, and evaluates therapeutic strategies targeting the microbiota–metabolite–immunometabolism axis.
- The result: The work frames dysbiosis as potentially perturbing immune homeostasis by rewiring host metabolic circuits, supporting microbiota-metabolite targeting as a promising therapeutic direction in IBD.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.